Replies to post #134216 on Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Agree. More than likely the afrticle will focus and discuss preclinical findings. I doubt there will be much clinical information.

[ImmunoATX]

1. Peer review of the data = increased legitimacy of the science, the clinical development team, and the company as a whole
2. Publication in a high impact journal = greater exposure to the science and clinical pipeline
3. Thorough explanation of the materials & methods, and a review of specific patient outcomes = further insight into the potential success of the drug
4. P21 data! Enough said.